|
|
News Breaks | | | | September 24, 2012 | | 07:06 EDT |  | NBY | NovaBay, Galderma enroll first patients in Phase 2b clinical study for NVC-422
Galderma S.A and NovaBay Pharmaceuticals announced that the first patients have been enrolled in the Companies' Phase 2b clinical study of a proprietary topical formulation of NVC-422, or CD07223, for the treatment of impetigo. The study is expected to enroll over 300 patients at 24 clinical sites in four countries worldwide and aims to confirm efficacy and evaluate 2 different dosage regimens. | |
|
News For NBY From The Last 14 Days Check below for free stories on NBY the last two weeks. |
|
|
| June 11, 2013 | | 08:10 EDT | | NBY | NovaBay provides mid-year update
NovaBay Pharmaceuticals announced several business and clinical updates for the remainder of 2013. NovaBay is conducting a Phase 2 clinical study of Auriclosene Flush Solution in the management of urinary catheter blockage and encrustation in patients with long-term indwelling catheters. Top-line results from the trial are expected in Q3. NovaBay has partnered with Galderma to develop Auriclosene Gel for treatment of highly contagious skin infection, impetigo, which occurs most commonly in children. Galderma expects to complete enrollment in Q3, and top-line results are expected in Q4. The Phase 2b trial, BAYnovation, is investigating Auriclosene Ophthalmic Solution as a treatment for adenoviral conjunctivitis, a highly contagious form of "pink eye." There is no approved treatment for this infection in the world. Enrollment in this trial began in May 2012 and is expected to complete in Q4. | |
|
|
|
|
|
|
